4-(2,2-二甲基丙基)嘧啶 | 28918-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-(2,2-二甲基丙基)嘧啶
• 英文名称: 4-(2,2-dimethyl-propyl)-pyrimidine
• 英文别名: 4-Neopentylpyrimidin；4-Neopentylpyrimidine；4-(2,2-dimethylpropyl)pyrimidine
• CAS: 28918-80-1
• 化学式: C₉H₁₄N₂
• 分子量: 150.224
• InChiKey: LVTKWUZEGSBNKS-UHFFFAOYSA-N

物化性质

• LogP：
  1.890 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4,4-二甲基-2-戊酮 、 醋酸甲脒 在 硫酸 、 正丁醇 、 crude product 作用下， 以 正丁醇 为溶剂， 反应 24.0h， 以Product 4-(2,2-dimethyl-propyl)-pyrimidine (˜5 g) is obtained的产率得到4-(2,2-二甲基丙基)嘧啶
  参考文献：
  名称：

  Pyrimidine derivatives and their use in perfume compositions

  摘要：

  本发明涉及新型嘧啶衍生物及其在香料组合物中的使用。本发明的新型嘧啶衍生物由以下公式表示：其中m和n是整数，当m为0时，n为1；当m为1时，n为0或1；或当m为2时，n为0；其中(CH)m和(CH)n各自独立地可选地被取代为从甲基和乙基组成的群体中选择的取代基；其中X从N、O和S中选择；且其中R1和R2各自独立地代表氢或一个碳氢基团，或者R1和R2一起代表一个融合环或一个环系统，但当R1为氢时，R2不为氢。

  公开号：

  US08557876B2

文献信息

• DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US20170002003A1

  公开（公告）日：2017-01-05

  The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

  本发明涉及二氮杂双环[4.3.1]癸烷衍生物，这些化合物的药用盐以及含有至少一种这些化合物的药用载体、赋形剂和/或稀释剂的药物组合物。所述的二氮杂双环[4.3.1]癸烷衍生物可用于预防和/或治疗精神障碍和神经退行性疾病、障碍和症状。
• TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.

  公开号：US20210277021A1

  公开（公告）日：2021-09-09

  Provided are a tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, provided are a tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as an angiotensin II type 2 receptor (AT 2 R) antagonist, wherein definitions of substituent groups in the general formula (I) are the same as definitions in the description.

  提供了一种四氢异喹啉衍生物，其制备方法及在医学中的应用。具体而言，提供了一种由通式（I）表示的四氢异喹啉衍生物，其制备方法及其药用可接受盐，以及其作为治疗剂的用途，特别是作为一种血管紧张素II类型2受体（AT2R）拮抗剂，其中通式（I）中取代基团的定义与描述中的定义相同。
• Substituted Benzamide Compounds
  申请人：Reich Melanie

  公开号：US20120071461A1

  公开（公告）日：2012-03-22

  Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

  对应于式(I)的取代苯甲酰胺化合物，其中R5、R6、R7、R8、a、b、c、d、t、D和X具有定义的含义，其制备方法，包括这些化合物的药物组合物，以及使用这些化合物治疗疼痛和其他至少部分通过激肽酶1受体介导的疾病的方法。
• Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors
  申请人：Addex Pharma S.A.

  公开号：US20140349994A1

  公开（公告）日：2014-11-27

  The present invention relates to novel compounds of Formula (I), wherein M and R 1 are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR 4 ”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR 4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR 4 is involved.

  本发明涉及式（I）的新化合物，其中M和R1如式（I）中所定义；该发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，对于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病具有用处。该发明还涉及制药组合物以及利用这类化合物制造药物的用途，以及利用这类化合物预防和治疗涉及mGluR4的疾病的用途。
• NICOTINAMIDES AS JAK KINASE MODULATORS
  申请人：Bauer Shawn M.

  公开号：US20120108566A1

  公开（公告）日：2012-05-03

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及具有公式I的化合物及其药用可接受的盐、酯和前药，这些化合物是JAK激酶的抑制剂。本发明还涉及用于制备这类化合物的中间体，该化合物的制备，含有该化合物的药物组合物，抑制JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由JAK激酶活性介导的多种疾病条件的方法，例如不良血栓形成和非霍奇金淋巴瘤。